BridGene Biosciences Closes $28M Series B+

Why It Matters

The capital infusion positions BridGene to fast‑track its pipeline of novel small‑molecule therapeutics, potentially unlocking treatments for diseases lacking effective drugs. Success could reshape biotech strategies for tackling undruggable targets.

Key Takeaways

• Series B+ raised $28 million for small‑molecule drug platform
• Bayland Capital led round, joined by GTJA, Proxima, others
• IMTAC™ chemoproteomics screens covalent molecules across live-cell proteome
• Targets traditionally undruggable proteins, expanding therapeutic possibilities
• Existing investors Lapam and Grains Valley reaffirm confidence in technology

Pulse Analysis

The biotech sector has seen a surge in mid‑stage financing as investors chase platforms that promise to overcome long‑standing scientific hurdles. BridGene’s $28 million Series B+ reflects a broader trend where venture capital backs companies that can de‑risk early discovery phases. By securing funds from both new and existing backers, BridGene not only validates its technology but also gains the runway needed to expand preclinical programs and attract strategic partners.

At the core of BridGene’s value proposition is its proprietary IMTAC™ (Isobaric Mass‑Tagged Affinity Characterization) chemoproteomic platform. Unlike conventional screening that targets isolated proteins, IMTAC interrogates the entire proteome within living cells, identifying covalent binding sites that were previously invisible. This holistic approach accelerates hit identification, reduces off‑target risk, and opens avenues to drug targets deemed “undruggable” by traditional small‑molecule methods. The platform’s ability to map covalent interactions in real‑time gives BridGene a competitive edge in discovering first‑in‑class therapeutics.

The market implications are significant. If BridGene can translate its proteome‑wide hits into clinical candidates, it could set a new benchmark for drug discovery efficiency, prompting larger pharmaceutical firms to adopt similar chemoproteomic strategies. Moreover, the confidence shown by investors such as Bayland Capital signals that the industry expects tangible returns from targeting hard‑to‑drug proteins, potentially reshaping R&D pipelines across the sector. As the company advances its pipeline, successful outcomes could catalyze further capital inflows and partnerships, reinforcing the momentum behind innovative biotech platforms.